SELB - Selecta Biosciences GAAP EPS of $0.04 beats by $0.11 revenue of $16.79M beats by $5.11M
- Selecta Biosciences press release ( NASDAQ: SELB ): Q4 GAAP EPS of $0.04 beats by $0.11 .
- Revenue of $16.79M (-43.8% Y/Y) beats by $5.11M .
- Selecta had $136.2 million in cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2022, as compared to cash, cash equivalents, marketable securities, and restricted cash of $129.4 million as of December 31, 2021. Selecta believes its available cash, cash equivalents, restricted cash, and marketable securities will be sufficient to meet its operating requirements into mid-2024.
For further details see:
Selecta Biosciences GAAP EPS of $0.04 beats by $0.11, revenue of $16.79M beats by $5.11M